Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01149421 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 755
- Enrollment target
NCT01149421: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT01149421 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 755 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (468% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01149421, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 755 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of 2 doses of LY2189265 on blood pressure and heart rate using 24-hour ambulatory blood pressure monitoring (ABPM), in participants with type 2 diabetes mellitus treated with oral antihyperglycemic medications (OAMs).
Primary Outcome
Mean 24-hour systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600.
Interventions
- DRUG Placebo
- DRUG LY2189265
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 755 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
What the finished NCT01149421 record still lists
NCT01149421 is an interventional study that assigns participants to a tested intervention. The registered 755 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (468% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01149421 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01149421 about?
NCT01149421 is a clinical study titled "A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes". The purpose of this study is to assess the effects of 2 doses of LY2189265 on blood pressure and heart rate using 24-hour ambulatory blood pressure monitoring (ABPM), in participants with type 2 diabetes mellitus treated with oral antihyperglycemic medications (OAMs).
What is the current status of trial NCT01149421?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 755 participants. The study started on 2010-06. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01149421?
The interventions under investigation include: Placebo (DRUG), LY2189265 (DRUG).
Who is sponsoring clinical trial NCT01149421?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01149421's enrollment target sits among peer trials
755 43rd of 2000 higher than 1,958 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05869149 · 756 participants · NA
Systems Science Approaches to Improve Access to Healthier Foods: The FRESH Trial
- NCT06095583 · 756 participants · Phase 3
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- NCT05379985 · 754 participants · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT05427370 · 754 participants · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia